Skip to main content

International investor influx in Southeast Asia

Geopolitical stability, gradually rising living standards and the introduction of universal healthcare systems is fuelling investor interest across Southeast Asia, particularly in Indonesia, which is home to the largest and fastest growing market.

Merck expands in Asia and proposes to acquire Australia’s Viralytics

Leading science and technology company Merck (known as MilliporeSigma in the US) has announced agreements in China, India and South Korea that will see the company invest €40 million in the region.

The company has signed an agreement with Incheon Free Economic Zone (IFEZ) to build an integrated cell culture facility in Songdo, Incheon. Located on 10,141m2 of land, the new centre will include cell culture media facilities and a logistics infrastructure. Construction is expected to begin in May 2018 and to be completed by mid-2019.

Will Brexit affect access to medicines?

Chris Gould, managing director at Active Pharma Ideas Ltd, examines the “Brexit balancing act” between patient access to medicines, industry’s concerns and the complexities facing those negotiating.
Subscribe to Pharmaceuticals




AMRI banner advert